Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5886_Библиотеки_им_академика_М_И_Перельмана.pdf
X
- •Foreword
- •Preface
- •Acknowledgements
- •Contents
- •Contributors
- •About the Editors
- •1.2.2.3 Progeria
- •1. Bioprocessing, Bioengineering and Process Chemistry in the Biopharmaceutical Industry: Using Chemistry and Bioengineering to Improve the Performance of Biologics
- •1.1 Introduction
- •1.2.2.2 Cystic Fibrosis
- •1.3.2.1 ADC Drugs
- •1.4 Top 25 Best-Selling Drugs
- •1.5.1 An Overview
- •1.5.2 Synthetic Biology
- •1.5.8 Biopharmaceutical Regulatory CMC
- •1.5.9 Technology Transfer
- •References
- •2.1 What Is Synthetic Biology?
- •2.6 CAR-T Cell Therapies
- •2.7 Conclusion
- •References
- •3.1 Introduction
- •3.2.1 Oligonucleotide Synthesis
- •3.2.1.1 Early Synthetic Chemistries
- •3.2.2 Solid Supports
- •3.2.3 Modern Oligo Synthesis Platforms
- •3.3 Gene Synthesis
- •3.3.1 Early DNA Assembly Methods
- •3.3.2 Array-Based Gene Synthesis
- •3.4 New Discovery Bottleneck
- •3.4.1.1 Hybridoma Technology
- •3.4.1.2 Phage Display Technology
- •3.4.1.3 Synthetic Antibody Library Construction
- •Semi-Synthetic Libraries
- •Fully Synthetic Libraries
- •3.5 Perspectives
- •References
- •4.1 Introduction
- •4.2.1 Batch
- •4.2.2 Fed-Batch
- •4.2.4 Hybrid Processes
- •4.2.7 Dynamic Perfusion Processes
- •4.3.2 Glucose Limitation
- •4.4.1 N-1 Perfusion
- •4.4.3 Linked Bioreactors
- •4.5 Process Analytical Technology
- •4.6 Single-Use Bioreactors (SUBs)
- •4.7 Conclusions
- •References
- •5.1 Introduction
- •5.2.1 Molecular Format Considerations
- •5.2.1.1 The Charge-Based Electrostatic Approach
- •5.2.1.2 The Knob into Hole Approach
- •5.2.2.1 Stable CHO Host Cell Integration System—Random or Targeted?
- •5.2.2.2 Expression Vector Considerations
- •5.2.2.3 Cell Line Screening Strategy Considerations
- •5.3.1 Upstream Process Development
- •5.3.2 Downstream Process Development Considerations
- •5.3.2.1 Unique Impurity Challenges
- •5.3.2.2 Stability Concerns
- •5.5.2.1 H/H Removal
- •5.5.2.2 HMMS Removal
- •References
- •6.1 Introduction
- •6.2.1 N-Linked Glycosylation
- •6.2.2 O-Linked Glycosylation
- •6.2.3 Glycosaminoglycan Synthesis
- •6.3.1 Mannosylation
- •6.3.2 Fucosylation
- •6.3.3 Galactosylation
- •6.3.4 Sialylation
- •6.5 Glycoengineering
- •6.5.1 Manipulating Heterogeneity
- •6.5.2 Manipulating Sialylation
- •6.5.2.1 Increasing α-2,6 Sialylation
- •6.5.3 Manipulating Fucosylation
- •6.5.4 Manipulating Branching
- •6.6.1 Temperature
- •6.6.2 pH
- •6.6.3.2 Amino Acids
- •6.6.3.3 Glycosaminoglycan Production
- •6.6.4 Culture Additives
- •References
- •7.1 Introduction
- •7.1.1 AAV Gene Therapy
- •7.3.1 Humoral Immunity
- •7.3.2 Cell-Mediated Immunity
- •7.4 Conclusion
- •References
- •8.1 Introduction
- •8.2 mRNA Vaccines
- •8.2.1 Background
- •8.2.2 Production Process
- •8.2.2.2 Production
- •8.4.1 Background
- •8.4.2 Production Process
- •8.4.2.2 Production
- •8.4.2.3 Viral Inactivation
- •8.5 Protein-Based Vaccines
- •8.5.1 Background
- •8.5.2 Production Processes
- •8.5.2.1 NVX-CoV2373 (Novavax)
- •8.3 Viral Vectors
- •8.3.1 Background
- •8.3.2 Production Process
- •8.3.2.2 Production
- •8.4 Whole Inactivated Virus Vaccines
- •8.5.2.2 CoVLP (Medicago)
- •8.5.2.3 EpiVacCorona (Vector Institute)
- •8.7 Conclusions
- •References
- •9. CAR-T Bioprocessing
- •9.1 Introduction
- •9.2.1 Introduction
- •9.2.2 Lentiviral Vector Design
- •9.2.5 Upstream Bioprocessing
- •9.2.6 Downstream Bioprocessing
- •9.3 Cell Product Bioprocessing
- •9.3.1 End-to-End Systems
- •9.3.4 Activation
- •9.3.6 Cell Expansion
- •9.3.8 T-Cell Cryopreservation
- •References
- •10.1.1 What Is CRISPR?
- •10.1.4 Mechanism Behind CRISPR Gene Editing
- •10.2.1 Creating Gene Knockouts
- •10.2.2 Creating Gene Knock-Ins
- •10.2.4 CRISPR Screens
- •10.3.1 Derivative Technologies
- •10.4.2 Delivery Methods
- •10.6.2 TCR Engineered T Cell Therapy
- •10.6.3 Chimeric Antigen Receptor T Cell Therapy
- •10.9.2 Safety Considerations
- •References
- •11.1 Introduction
- •11.1.2 Categories
- •11.2 Current Status
- •11.2.1 Approved Products
- •11.2.2 Market
- •11.3 Design
- •11.3.1 Building Blocks
- •11.3.2 Linkers
- •11.3.3 Oligomerization
- •11.3.3.1 Monomer
- •11.3.3.2 Dimer
- •11.3.3.3 Trimer
- •11.3.3.4 Tetramer
- •11.3.3.5 Pentamer
- •11.3.3.6 Hexamer
- •11.3.3.7 Octamer
- •11.3.4 Orientation
- •11.3.5 Protein Engineering
- •11.3.6 Immunogenicity
- •11.4 Manufacturing
- •11.4.1 Upstream
- •11.4.2 Downstream
- •11.4.3 Glycosylation
- •11.4.4 Aggregation
- •11.4.5 Analytics
- •11.5 Therapeutic Concepts
- •11.5.1 Half-Life Extension
- •Albumin Fusions
- •Fc Fusions
- •Transferrin Fusions
- •Repetitive Peptide Fusions
- •Glycosylated Peptides
- •11.5.1.3 Aggregate Forming Peptides
- •11.5.2 Targeting Functions
- •11.5.3.1 Fc Domain Receptor-Mediated Toxicity
- •11.5.3.2 Toxins
- •11.5.3.3 Immunocytokines
- •11.5.3.4 Human Enzymes
- •11.5.3.5 Apoptosis Induction
- •11.6 Summary
- •11.7 Future Perspectives
- •References
- •12.1 Introduction
- •12.2 ADC History
- •12.3 Target Selection
- •12.4 Antibody Selection
- •12.6 ADC Technology
- •12.7 ADC Clinical Development
- •12.8.1 Mylotarg
- •12.8.2 Adcetris
- •12.8.3 Kadcyla
- •12.8.4 Besponsa
- •12.8.5 Polivy
- •12.8.6 Padcev
- •12.8.7 Enhertu
- •12.8.8 Trodelvy
- •12.8.9 Blenrep
- •12.8.10 Zynlonta
- •12.8.11 Tivdak
- •12.9 Concluding Remarks
- •References
- •13.1 Introduction
- •13.2 Gemtuzumab Ozogamicin
- •13.3 Gemtuzumab Antibody
- •13.4 Calicheamicin
- •13.7.3 Isolation of N-Acetyl Calicheamicin
- •13.10 Conclusions
- •References
- •14.1 Introduction
- •14.2.1 Antibody Generation
- •14.3.1 Structure Prediction
- •14.3.2 Biophysical Properties
- •14.3.3 Hydrophobicity
- •14.3.5 Isoelectric Point (pI)
- •References
- •15.1 Introduction
- •15.2 ADA Program Development
- •15.2.3 Project Approach
- •15.2.4 Model Library
- •15.3 Case Study
- •15.3.3 Hypothesis Generation
- •15.3.5 Feature Engineering Example
- •15.3.7 Model Insights
- •References
- •16.1 Introduction
- •16.1.1.1 United States
- •16.1.1.2 European Union
- •16.1.2 Global Markets
- •16.4.1 United States FDA
- •16.4.2 European Medicines Agency (EMA)
- •16.4.3 The World Health Organization
- •References
- •17.1 Introduction
- •17.3.1.2 Clone Selection

90
G. W. Hiller
culture science would then be to determine the other by-products and devise methodologies to limit or control their formation. Easier said than done! We will touch
on such efforts later in this chapter, but for now remind the reader that “the solution
to pollution is dilution,” or in the case of cell culture…perfusion. Perfusion is the
brute force method that will solve nearly any waste product accumulation problem.
However, if the waste product is merely lactate, perfusion is a very inefcient
method of keeping lactate below a growth inhibitory concentration [29, 46]. A much
more efcient way to implement perfusion is to allow cells to control their own
perfusion rate and simultaneously reduce net lactate production to near zero. This
can be accomplished by modifying and extending the HiPDOG control scheme to
work with perfusion [9]. The technique can reduce by several fold the rate of perfusion required to maintain a culture in an exponential growth state and allow us to
coin yet another cute acronym, HiPCOP, or Hi-end pH Control Of Perfusion. Instead
of controlling the rate of nutrient addition to a fed-batch culture, now when the pH
reaches a high-end set point (indicating the culture is limited for glucose) a pump is
activated that delivers perfusion media containing glucose to the culture, while a
second pump maintains the volume of the culture constant by removing an equal
amount of liquid from the culture through a cell retention device. In a similar manner to the HiPDOG control, the addition of perfusion media via HiPCOP stops
when the pH drops back below the high-end set point as a small amount of lactic
acid is produced. However, at this point the astute cell culture scientist would realize
the fundamental problem with this this approach. The control of lactic acid formation would almost be too good in this case. Recall that when HiPDOG was used
with fed-batch cultures the lactate concentration would slowly fall throughout the
course of a culture since other acidic metabolic by-products partially interfered with
the control. Even with many dozens of CHO cell lines tested with HiPDOG in fed
batch, provided the initial glucose level of the culture was high enough, the level of
lactate never fell too low for the HiPDOG control scheme to continue to operate
effectively during the growth phase. However, in the case of perfusion, with the
simultaneous reduction in lactate concentrations just due to the perfusion operation
itself (the ushing of the pollution, remember?), reduction in lactate to near zero
could be a real possibility and might cause the HiPCOP control scheme to fail,
overly restricting the perfusion rate and slowing cell growth.
Upon realizing this complication, in our laboratory we began adding sodium-Llactate to the incoming perfusion medium at low levels to ensure that there would
always be a low level of lactate in the perfusion bioreactor culture so that the HiPCOP
control scheme would not fail. While almost a blasphemous proposal to add lactate
to a culture when for the last few decades we were trying to minimize lactate formation in mammalian cell culture, it seemed pragmatic initially. We found, however,
that pure sodium-L-lactate is not an inexpensive raw material. Far less expensive is
the racemic mixture of D/L-lactic acid which is a by-product of certain industrial
processes, and seems to be well tolerated when added to cell cultures. However,
since the D form of lactic acid is not readily consumed by mammalian cultures, it
would be an extra ion contributing to osmotic strength and the chemical mixture
itself would be another raw material requiring suitable sourcing. In continued experimentation and understanding of the chemical and biochemical processes occurring

4 Advancements in the Manufacture of Monoclonal Antibodies and Other Large…
91
in these cell cultures, it was realized that just as in fed-batch cultures where HiPDOG
control was partially decoupled due to the formation of other acidic species, a perfusion culture with HiPCOP control could be continuously maintained at a higher (but
still relatively low and controlled) lactate level merely by continuously forcing the
pH up independent of the HiPCOP control scheme. This could be accomplished with
a continuous slow addition of sodium carbonate titrant or by the continuous ashingoff of carbon dioxide (a removal of carbonic acid if you will) coming from perfusion
media entering the bioreactor. The perfusion media was modied to have slightly
higher than normal levels of sodium bicarbonate [47]. While carbon dioxide removal
can sometimes be an issue with scale up of cell culture processes, a simple calculation reveals that the amount of additional carbon dioxide necessary to be removed
from a perfusion culture using extra sodium bicarbonate in the perfusion media is a
small fraction of that needed to be removed simply due to the metabolism of glucose
to carbon dioxide in the tricarboxylic acid cycle.
4.3.5 “Whack aMole” withInhibitory By-products
The techniques discussed in the above sections describe methods to control lactate
and ammonium accumulation, and, at least with perfusion culture, ush out everything else that might be slowing growth. Ideally, however, to minimize process complexity, we’d prefer not to use perfusion at all and just keep cells growing to ever
higher peak densities in simple fed-batch culture. We determined early on that lactate accumulation was the primary factor limiting cell growth in our cultures [23],
but once that was controlled, we could start to see the “forest for the trees,” that is,
we began to see all the other inhibitors being formed when previously all we could
see was lactate. We conducted a series of experiments which ruled out a number of
other potential reasons and conrmed that the primary factor causing cessation of
CHO cell growth was the accumulation of small molecular weight chemical compounds that were by-products of cellular metabolism [42]. A wide range of metabolism by-products were identied and eventually quantitated by NMR (nuclear
magnetic resonance) and LC/GC-MS (liquid chromatography/gas chromatography—mass spectroscopy). The levels of their accumulation in fed-batch cultures as
cell growth slowed were determined, and a painstaking analysis directed by conventional understandings of mammalian cell metabolism pathways was performed to
determine the growth inhibitory potential of each compound.
While most of these compounds accumulate in fed-batch cultures to only submillimolar concentrations, or at most single to low double digit millimolar concentrations, the compounds had independent and synergistic negative effects on cell
growth. When added back to CHO cell cultures as pure chemicals in the ratios and
levels to which they accumulate when growth ceases in CHO cell fed-batch culture
experiments, the inhibitors could be shown to completely shut down all cell division. The biochemical pathways which produce the various inhibitors were then
investigated and potential strategies for dealing with the most potent inhibitors were
devised.

92
Many of the more potent inhibitors were found to be by-products of amino acid
catabolism. It was found that simply keeping the levels of a number of amino acids
below a certain upper threshold level, while simultaneously not allowing them to be
completely depleted, could minimize the formation of some inhibitors and enable
additional cell growth [42]. However, as with early efforts of cell culture scientists
to measure and precisely feed glucose and keep it in a lower range to limit lactate
formation, it was realized that other metabolic engineering approaches might be
more straightforward and could be implemented across the board for CHO host cell
lines. It was realized that three of the inhibitors: isovalerate, 2-methylbutyrate, and
isobutyrate, which were primarily formed from leucine, isoleucine, and valine
catabolism, respectively, shared the same enzyme at the beginning of their catabolic
pathway. Efforts were made to knock out the enzyme—branched chain amino acid
transaminase-1, or BCAT1. The resulting CHO cell lines grew to higher cell densities, maintained higher cell viability longer, and when transfected with the appropriate genetic elements also produced higher levels of recombinant proteins in
fed-batch and perfusion cultures than CHO cells without the knockout [48].
Of course, even fed-batch cultures of these BCAT1 knock out cells eventually
reach a peak cell density and cease division. Provided the cultures were appropriately fed required nutrients, logically these cultures also stopped division due to
some other inhibitory by-products. Further investigation suggested that in CHO
cells, missing or low levels of certain enzymes in the catabolic pathway of phenylalanine and tyrosine might be leading to the formation of other inhibitory compounds. In this case increasing the level of several of these enzymes (and even
adding back a co-factor pathway!) reduced the level of the inhibitor production and
had the added benet of making the cells no longer require exogenous additions of
tyrosine [48].
Our laboratory continues in this effort to determine each inhibitory factor that
might be appreciably limiting the maximum cell density reachable in fed-batch cultures, or that might require the use of higher levels of perfusion in processes that
resort to perfusion to maintain exponential growth. We are currently investigating
the implementation of the most benecial and pragmatic metabolism modications
directly into the CHO host cell lines used for expression of therapeutic proteins in
large-scale production.
G. W. Hiller
4.4 Other Methods ofProcess Intensication
4.4.1 N-1 Perfusion
As was mentioned earlier in this chapter, there are signicant advantages to increasing the IVCD, or the area under the curve of a viable cell density versus time graph.
This is because cells act as the workhorses, catalyzing the conversion of the amino
acids into the polymer, which is the protein therapeutic. Provided that specic productivity is maintained appropriately, more cells equal more stuff. The working

4 Advancements in the Manufacture of Monoclonal Antibodies and Other Large…
93
volume and efcient utilization of the production bioreactor are typically the principal limiting factor that determines the overall annual productivity of any manufacturing facility. Therefore, there is incentive to have that vessel lled with the highest
density of healthy cells at all times. Any time used during the expansion of the cell
mass in the production bioreactor is potentially wasted time. With this in mind it is
logical to minimize the time in the production bioreactor during which the cells are
dividing. N-1 (or seed bioreactor) perfusion can help to achieve this.
For reasons discussed earlier, perfusion allows for the maintenance of a much
higher number of cells in a bioreactor when compared with simple batch or fed
batch. When large volumes of media are perfused through a cell mass that is retained
within the bioreactor by a cell retention device, very high cell densities can be
achieved. However, there are limits to the practicality of N-1 perfusion. At cell densities above 100 × 106 cell/mL the properties of the uid can begin to change merely
due to the fact that a signicant fraction of the uid is occupied by cells [8].
Viscosities can signicantly increase making it difcult to move cells in and out of
a cell retention lter, particularly if a vacuum diaphragm pump is being utilized for
generating such ow. The cell retention lters can also reach the limits of ltration
capacity, though this is mitigated to some extent by the fact that the rapidly dividing
cell mass of an N-1 bioreactor is typically at very high viability. At extremely high
viable cell densities, oxygen transfer in, and carbon dioxide removal from the bioreactor can become problematic, particularly when foaming starts to occur.
Interruptions to gas supply in such cultures can drop the dissolved oxygen to near
undetectable levels within less than a minute.
Most large-scale mammalian cell culture manufacturing facilities use a 1:5 volume ratio for each step of their scale up train, and this also typically includes the
nal seed bioreactor. If we assume for the moment that 100 × 106 cell/mL is a reasonable practical limit for the maximum density achievable in the N-1 seed bioreactor, that means that the maximum inoculation density in the production bioreactor
would be about 20 × 106 cell/mL, or slightly higher as 20–30% of the volume of the
production bioreactor must be left available for the fed-batch feeds that will occur
later. If the N-1 bioreactor were instead merely a batch or fed-batch bioreactor the
maximum inoculation density of the production bioreactor might be closer to 1 or 2
× 106 cell/mL which is more typical of platform cell culture processes today. As
exponential growth doubling times are only around 24hours for mammalian cell, a
20 × 106 cell/mL inoculation coming from an N-1 culture using perfusion could
potentially shave three to 4 days off the typical 12–18-day length of a production
bioreactor operating in fed-batch mode and still yield equivalent or higher titers
[49, 50].
4.4.2 N-1 Intensication
N-1 perfusion is the extreme example of N-1 intensication to enable higher production bioreactor inoculations, but a well-managed N-1 fed-batch culture can also
provide sufcient cells to accelerate the production bioreactor. The key here is to

94
G. W. Hiller
provide cells that have not overgrown and are therefore not likely to suffer a lag in
the production bioreactor. The HiPDOG glucose limiting strategy has been shown
to accomplish this for N-1 cultures [23], but any technique that reduces the formation of growth inhibitors, such as those that were discussed in the earlier sections of
this chapter, will also serve the same purpose provided the method does not overly
extend the length of the N-1 culture.
4.4.3 Linked Bioreactors
In the last section we investigated and demonstrated the logic of increasing the
inoculation density of the production bioreactor. If one follows this to the extreme,
we see the value in having the production bioreactor at the highest viable cell density possible all the time. There are practical limits to the length of a fed-batch bioreactor operation as we explored in the section on fed batch. Briey revisiting,
anything the cells produce (including all waste products) remains in the culture, as
does anything fed to the culture but not consumed by the cells. In addition, dying
cells can release the contents of their cytoplasm and various organelles to the culture
milieu. Depending upon the stability of the protein product, 10–18days in such a
mixture of various enzymes and cellular components might be problematic to product quality. Quiescent cells also have limits to their ability to withstand deteriorating
culture conditions as waste products accumulate and the osmotic strength of the
culture continuously increases. Late in a deteriorating culture, cells also sometimes
revert to a more glycolytic metabolism leading to increases in lactate and sometimes
also in ammonium. Lower viability cells are also more likely to truncate the glycosylation process resulting in product material with lower levels of sialylation, less
terminal galactosylation, and increased levels of high mannose species. In
short…things go bad when the cells get tuckered out!
We noted earlier that the commonly observed phenomenon that cells with low or
near zero growth rates also tend to have higher per cell, or specic productivities.
Also, the optimum conditions for cell division might not be the optimum conditions
for the production of the protein, especially if it is found that some particular product quality parameter can best be optimized at an extreme of the normal growth
range (pH or temperature for instance). While we can certainly change conditions
post-growth phase in a fed-batch production bioreactor, it may take cells time to
adapt to the new conditions and some signicant fraction of product will be produced during the growth phase under the unfavorable environmental parameter for
product quality.
Some of the above, long recognized limitations of fed-batch culture might be
mitigated by completely separating the growth and production phases that usually
occur in the production bioreactor. This can be achieved by linking two bioreactors
together in continuous operation. The N-1 bioreactor continuously supplies cells
dividing near the maximum growth rate to a production bioreactor where conditions
are more conducive to a low-growth but highly productive, somewhat quiescent

4 Advancements in the Manufacture of Monoclonal Antibodies and Other Large…
95
state. The cells entering the production CSTR (continuous-ow stirred-tank reactor)
perhaps undergo one more division (recall the “division momentum” mentioned in
an earlier section) before adapting to the production bioreactor conditions which are
optimal for protein production. While certainly a more complex operation, such a
linked bioreactor system can be very productive.
The simplest version of such a linked bioreactor system would be a pair of cascading CSTR’s or chemostats [51]. If one were to make use of most existing largescale cell culture facilities this would generally mean a 1–5, or 1–10 volume ratio of
the N-1 to production bioreactor. The cascading CSTR system, however, suffers
from the fact that the maximum dilution rate of the N-1 bioreactor is limited to the
washout dilution rate, which for mammalian cells is not much above 1/day or 1
VVD.Even near that washout dilution rate the cell density in the N-1 would be low
and the overall number of cells per unit time delivered to the production bioreactor
would be low. Cells in an N-1 bioreactor operating at dilution rates much below the
washout rate would by default be growing slower, and therefore on average less
likely to continue division when transferred to the production bioreactor. So, we see
that the N-1 operating as a CSTR signicantly restricts the operating parameters
and therefore the number of cells the bioreactor can produce per day. Introducing
perfusion/cell retention in the N-1 removes this constraint and allows for high perfusion rates, very high growth rates, and enormous quantities of cells for transfer to
the production reactor. If the production bioreactor then operates as a simple CSTR
or chemostat (no cell retention), with additional nutrients added directly to it, volumetric productivities approaching or exceeding those in a stand-alone continuous
perfusion bioreactor, ~1g/L/d, may be achieved [52]. In such a system, the additional complexity of requiring a cell retention system on the largest vessel, the production bioreactor, is eliminated. Such a linked-bioreactor system could deliver
harvest (containing whole cell culture) continuously to a suitably designed continuous downstream operation, or could even be cycled slightly in working volume,
allowing bolus harvests to be taken once a day or once per 2 days.
To be efcient, a linked-bioreactor system must reach a high-productivity steady
state quickly. It is therefore important in this reactor conguration not to overshoot
the sustainable cell density as this could lead to a loss of cell viability. Getting to the
highest productivity state might take additional time when compared to a standard
fed-batch culture as the cells in the production bioreactor need to adapt to the conditions that are ultimately controlled by the dilution rate and rate of addition of cells
and nutrients. To be a practical way to produce protein, and to demonstrate the
advantage over fed-batch, a linked-bioreactor system would need to be operated for
a comparatively long period of time; at least several weeks and perhaps ideally continuously for several months. At rst glance, this may present a problem as genetically engineered cells have varying degrees of genotypic stability for production of
the recombinant protein. The limit of such genotypic stability is generally demonstrated for any industrial cell culture process when the “limit of in vitro cell age” or
LIVCA study is performed to determine how often a production facility needs to
return to the working or master cell banks to expand cells for additional production
batches.

96
G. W. Hiller
The potential longevity of the linked culture system was demonstrated in our labs
with the continuous operation of a linked-bioreactor system for over 80days [52].
Additionally, it was established that the N-1 bioreactor (and ultimately the production bioreactor) could be “refreshed” by expanding again from frozen vials using a
second parallel or twin N-1 bioreactor and switching the stream of cells entering the
production bioreactor from the N-1 bioreactor containing the “old” cells to that
containing the “new” cells. Performed correctly, it was shown that the viable cell
density and volumetric productivity of the production bioreactor can remain nearly
constant through this transition. This allows for the production bioreactor to operate
nearly indenitely in a very high volumetric productivity steady state, with a regularly “rejuvenated” set of cells (if only this could be replicated for humans!) producing product continuously with nearly identical product quality parameters. Since
cells in the production bioreactor CSTR divide much slower than those in the N-1
culture, cells in the production CSTR that have accrued a larger number of generations are washed out of the system over time at a rate that depends upon the dilution
rate of the production bioreactor among other factors.
The linked-bioreactor system just described provides volumetric productivities
approximately double that of an optimized fed-batch process, and nearly as high as
a stand-alone steady-state perfusion bioreactor, without the need for perfusion in the
production bioreactor. This may decrease the size of the cell retention system by a
factor of ve or perhaps ten. For high demand products, production bioreactors in
mammalian cell culture facilities are often in the 13,000-L working volume range,
meaning that the N-1 reactor might be 2500 or perhaps as small as 1000-L working
volume. Still, performing long term consistent perfusion using conventional microltration methods at such a scale might give some cell culture engineers nightmares.
4.4.4 Hydrocyclone Use withLinked Bioreactors
As mentioned earlier in this chapter in the section on perfusion, a great many clever
cell retention devices have been developed over the past few decades but scale up
for use on mammalian cells in suspension in bioreactors in the 1000L range of any
but the microltration methods have been particular problematic. Long used in
microbial culture harvest and in mining and oil extraction industries, one cell retention system that seemed particularly promising for scale up was the hydrocyclone
[53, 54]. While early experiments suggested that mammalian cells could withstand
the very high shear forces generated as cells passed through a hydrocyclone [55],
generally their use for cell retention in mammalian cell culture did not catch on
widely, with very few mentions in the literature throughout 2005–2020. This may
be because while highly viable cells dividing at near exponential growth rates might
be able to withstand the shear forces, cells in perfusion production bioreactors are
often not growing quickly because conditions that favor fast growth often cause per
cell productivity to be lower. Alternatively, if used for an N-1 perfusion culture for
the generation of large amounts of cells for a single inoculation of a production

4 Advancements in the Manufacture of Monoclonal Antibodies and Other Large…
97
bioreactor, hydrocyclones also suffer when compared with membrane cell retention
devices due to their somewhat low separation efciency. As a result, it might take
several additional days for an N-1 perfusion bioreactor using a hydrocyclone to
reach a sufciently high cell density to inoculate a production bioreactor at high
density. Finally, while running multiple hydrocyclones in series might seem like a
method to increase the efciency of the cell separation, the additional pressure drop
required might prove too extreme of a shear environment for mammalian cells to
survive.
While hydrocyclones have the benet of being very unlikely to plug with cell
debris, even fairly optimized geometry hydrocyclones lose too many cells to the
perfusion stream. The additional signicant advantage of the hydrocyclone, its
scale-up capacity, could even be considered a disadvantage as scaling down a hydrocyclone for use in bench scale bioreactors is problematic. The best way to scale
down a hydrocyclone is merely to turn it on and off periodically by stopping the
pump that delivers cell culture uid to it. When running continuously, a hydrocyclone the size of a 50-mL centrifuge tube is sufcient to process ~500L of cell
culture uid a day.
Understanding the limitations of hydrocyclones—low efciency and high shear
forces making them suitable only for high viability and shear resistant cells—our
laboratory experimented with their use as a cell retention device in the linked bioreactor system [56]. In this system, cells in the N-1 bioreactor were typically dividing
at near exponential growth rates, and the overow uid from the hydrocyclone (the
permeate uid that had reduced numbers of cells) could be used as the cell source
for the continuously linked production bioreactor operating as a CSTR. In this
highly specialized use, the hydrocyclone was nearly ideal as it would not plug, and
a pair of 3-D printed then autoclaved hydrocyclones operating in parallel, fed by a
single high-ow pump, could be shown to be sufcient to perfuse a 1000-L N-1
bioreactor at 1 VVD.Coupled with a production bioreactor operating as a CSTR
with a working volume of 10,000 to possibly 13,000L the system could achieve
volumetric productivities near those of the linked system using a microltration
membrane for N-1 perfusion, ~1g/L/day [52].
4.5 Process Analytical Technology
Process analytical technology is fancy terminology that merely describes sensors
for the continuous monitoring and control of parameters such as dissolved oxygen,
pH, and temperature that have been in place on bioreactors for many decades. New
sensors are always being developed, some of which may have pragmatic applications, while others seem to be searching about for practical value. Dissolved carbon
dioxide probes, conductivity or capacitance probes for cell density approximation,
and foam sensors are certainly of increased value as mammalian cell culture processes continue to be intensied.

98
G. W. Hiller
The reliability, accuracy, and durability of dissolved carbon dioxide probes have
certainly improved in recent years; however, it should be mentioned that extreme
accuracy is not necessary for a carbon dioxide probe to yield valuable information.
High intensity cultures with very high oxygen demands that often require use of
pure oxygen and small bubble generating sparge elements can frequently suffer
from high levels of dissolved carbon dioxide. Allowing the level of dissolved carbon
dioxide to rise above approximately 12% of saturation can slow cell growth, and in
some cases affect product quality parameters [28, 57]. While the two parameters,
oxygen delivery and carbon dioxide removal, are certainly closely interlinked, large
scale operations with highly intensied processes at our facilities have found it
practical to independently control these parameters. Dissolved oxygen is controlled
via the delivery of tiny pure oxygen bubbles from suitable spargers. Dissolved carbon dioxide is continuously measured using an in situ probe and is maintained
below a target high-end setpoint by sparging either air or pure oxygen through
sparge elements that deliver large volumes of gas and generate larger bubbles than
those used exclusively for oxygen delivery.
If they make it to the surface without completely dissolving, the high efciency
oxygen transfer afforded by small bubbles of pure oxygen also can create a very
stable foam layer, particularly in a culture with high cell densities and high levels of
dissolved protein. Cell entrapment into foam has long been identied as potential
source of high shear forces capable of killing cells as the bubbles burst [58].
Additionally, if allowed to reach the vent lter such foam can quickly plug vent
lters, increase bioreactor hydrostatic pressure, and greatly restrict the ability to
continue to sparge the bioreactor. Many forms of foam sensors are available from
various industrial processes, but some may be difcult to implement in an aseptic
fashion, particularly on the many single-use bioreactor designs being adopted today.
Our pilot and large-scale facilities are currently adopting automated control systems
with cameras and light strobes that can accurately estimate the foam layer and
deliver antifoam as necessary to reduce the likelihood of vent plugging. Such a noninvasive foam control system merely requires a modestly clear window for a view
down onto the culture surface.
Conductivity or capacitance probes measure the total volume of cells with intact
cell membranes. Generally, this can be closely correlated with the number of viable
cells in the culture, at least while the cells are growing quickly [46]. As manual or
even computer assisted cell counts performed via automated microscopic methods
are subject to signicant variability due sample handling and dilution errors, a
capacitance probe can better indicate the true growth rate of the culture. Since even
slight changes in growth rate can over time result in signicant differences in cell
density, a continuous, precise knowledge of the biomass of a culture can assist in
delivering concentrated feeds at appropriate rates to a culture, or assist in controlling perfusion rates to maintain a constant cell-specic perfusion rate. Unfortunately,
later in culture the capacitance probe readings and the actual viable cell density can
start to deviate from the strong correlation earlier in the process. This may occur
because late in culture sometimes cell size increases without additional division. We

4 Advancements in the Manufacture of Monoclonal Antibodies and Other Large…
99
have found that oxygen consumption rates, or even merely the value of the oxygen
delivery rate of a culture that has controlled dissolved oxygen levels can sometimes
be used in conjunction with capacitance probe values to estimate the viable cell
mass and adjust feeding rates.
In situ, autoclavable probes for Raman spectroscopy can simultaneously collect
spectra that can be used to quantitate a whole range of cell culture parameters.
Factors such as glucose, lactate, and even certain amino acid concentrations can be
correlated to the appropriately analyzed Raman signal; however, the ability to accurately determine any of these metabolites at low concentrations (below 3–5mM) is
extremely limited [59–61]. Also, unfortunately, the Raman calculated value for any
of these parameters can be affected by a large number of factors that change throughout the culture. As a result of this, to accurately predict the concentration of a substrate or by-product in a culture it may be necessary to go through the somewhat
laborious process of creating a large data set of Raman spectra on many bioreactor
runs with minor process differences. This “teaching” spectra can be used with an
orthogonal method of accurately quantitating the parameter, ultimately generating
an algorithm which in the future can be used to calculate the parameter directly
from the Raman spectra.
Through the process described above, our laboratory was able to continuously
approximate the concentration of both glucose and lactate using Raman spectroscopy [60]. We realized that there could be some value in the number, even if only
approximate. We surmised that even knowing the concentration of the value of glucose and lactate combined within the range of 1–2g/L could allow us to control the
rate of glucose feeding. As mentioned earlier in the section on control of cellular
metabolism, during the growth phase if a cell culture becomes limited for glucose it
will often begin to consume lactic acid from the culture. So, monitoring the combined concentration of glucose and lactate and feeding glucose in an attempt to keep
the combined value nearly constant should minimize the formation of lactate. Of
course, the same result could be achieved merely using the HiPDOG control strategy without all the added Raman correlation experiments; and certainly an autoclavable pH probe is far less expensive (and nearly ubiquitously implemented) than
a Raman probe for every bioreactor. In certain circumstances when the HiPDOG
control strategy might be undesirable Raman might prove useful.
Raman might also be utilized to better control in an automated fashion the mass
load of antibody to the rst column chromatograph step (e.g., protein A afnity). As
part of an integrated downstream purication process, our laboratory is currently
evaluating Raman to determine the antibody concentration of permeate leaving the
microltration cell retention system of a perfusion bioreactor. Unfortunately, as
with other uses of Raman spectroscopy, we have found it may be necessary to generate a complete set of “learning spectra” for each new antibody molecule despite
the assumed similar properties that antibodies with only changes to the antigen
binding site would have.
Соседние файлы в папке Библиотека им академика М.И. Перельмана
